<DOC>
	<DOC>NCT00514904</DOC>
	<brief_summary>The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects</brief_title>
	<detailed_description>Multicentre study with 2 treatment groups. Two blood samples will be taken, prior to and one month after vaccination, from the first 75% enrolled subjects per country independent of the treatment group.</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that their parents or guardians can and will comply with the requirements of the protocol. A male or female between, and including, 2 and 10 years of age at the time of vaccination. Written informed consent obtained from the parent or guardian of the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs within six months prior to the first vaccine dose. Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine. Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W135 and/or Y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above). Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroups A, C, W135 and/or Y. Previous vaccination with tetanus toxoid within the last month. History of meningococcal disease. Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.. History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s). Major congenital defects or serious chronic illness. Acute disease at the time of enrolment. Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>immunogenicity</keyword>
</DOC>